ProPhase Labs Statistics
Total Valuation
ProPhase Labs has a market cap or net worth of $14.58 million. The enterprise value is $43.67 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, before market open.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ProPhase Labs has 23.87 million shares outstanding. The number of shares has increased by 10.53% in one year.
| Current Share Class | 23.87M |
| Shares Outstanding | 23.87M |
| Shares Change (YoY) | +10.53% |
| Shares Change (QoQ) | +1.01% |
| Owned by Insiders (%) | 13.96% |
| Owned by Institutions (%) | 7.83% |
| Float | 20.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.89 |
| Forward PS | 0.11 |
| PB Ratio | 0.31 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of 0.78.
| Current Ratio | 1.47 |
| Quick Ratio | 1.12 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.60 |
Financial Efficiency
Return on equity (ROE) is -58.71% and return on invested capital (ROIC) is -30.95%.
| Return on Equity (ROE) | -58.71% |
| Return on Assets (ROA) | -24.12% |
| Return on Capital (ROIC) | -30.95% |
| Revenue Per Employee | $112,858 |
| Profits Per Employee | -$245,628 |
| Employee Count | 113 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 3.74 |
Taxes
| Income Tax | -10.28M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.43% in the last 52 weeks. The beta is -0.30, so ProPhase Labs's price volatility has been lower than the market average.
| Beta (5Y) | -0.30 |
| 52-Week Price Change | -86.43% |
| 50-Day Moving Average | 1.34 |
| 200-Day Moving Average | 3.39 |
| Relative Strength Index (RSI) | 24.32 |
| Average Volume (20 Days) | 237,091 |
Short Selling Information
The latest short interest is 144,903, so 0.61% of the outstanding shares have been sold short.
| Short Interest | 144,903 |
| Short Previous Month | 245,646 |
| Short % of Shares Out | 0.61% |
| Short % of Float | 0.71% |
| Short Ratio (days to cover) | 7.04 |
Income Statement
In the last 12 months, ProPhase Labs had revenue of $12.75 million and -$27.76 million in losses. Loss per share was -$1.51.
| Revenue | 12.75M |
| Gross Profit | -4.13M |
| Operating Income | -35.41M |
| Pretax Income | -32.20M |
| Net Income | -27.76M |
| EBITDA | -27.88M |
| EBIT | -35.41M |
| Loss Per Share | -$1.51 |
Full Income StatementBalance Sheet
The company has $503,000 in cash and $29.59 million in debt, giving a net cash position of -$29.09 million or -$1.22 per share.
| Cash & Cash Equivalents | 503,000 |
| Total Debt | 29.59M |
| Net Cash | -29.09M |
| Net Cash Per Share | -$1.22 |
| Equity (Book Value) | 38.13M |
| Book Value Per Share | 2.00 |
| Working Capital | 13.54M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.18 million and capital expenditures -$2.45 million, giving a free cash flow of -$16.63 million.
| Operating Cash Flow | -14.18M |
| Capital Expenditures | -2.45M |
| Free Cash Flow | -16.63M |
| FCF Per Share | -$0.70 |
Full Cash Flow StatementMargins
Gross margin is -32.38%, with operating and profit margins of -277.69% and -217.64%.
| Gross Margin | -32.38% |
| Operating Margin | -277.69% |
| Pretax Margin | -298.21% |
| Profit Margin | -217.64% |
| EBITDA Margin | -218.61% |
| EBIT Margin | -277.69% |
| FCF Margin | n/a |
Dividends & Yields
ProPhase Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.53% |
| Shareholder Yield | -10.53% |
| Earnings Yield | -190.43% |
| FCF Yield | -114.11% |
Dividend DetailsAnalyst Forecast
The average price target for ProPhase Labs is $11.00, which is 1,701.80% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $11.00 |
| Price Target Difference | 1,701.80% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on January 23, 1997. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 23, 1997 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ProPhase Labs has an Altman Z-Score of -0.43 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.43 |
| Piotroski F-Score | 1 |